A new meningitis vaccine used in the USA has been successfully tested on babies in the UK and Canada.
A randomised trial assigned 225 and 196 UK and Canadian infants to receive a primary course of the MenACWY vaccine for two years.
The study found that MenACWY was well tolerated and at least 92% of babies who had the vaccine at ages 2, 3 and 4 months had sufficient antibodies against four strains of the disease.
Twelve month boosters increased protection considerably against the first three disease strains.
The study authors commented: "We have demonstrated that a primary immunisation course of the novel treatment meningococcal glycoconjugate vaccine MenACWY was well tolerated and immunogenic … when given to healthy infants at either 2, 3 and 4 months or 2, 4, and 6 months of age."